Date Range
Type of Content
Author
Category
Commentary
Canada should permanently expand drug approval process in post-COVID world
Appeared in the Appeared in National Newswatch
| by:
Dr. Nigel Rawson
Commentary
Environmental appraisals for new gene therapies may limit new drugs in Canada
Appeared in the Appeared in Calgary's Business
| by:
Dr. Nigel Rawson,
and Mackenzie Moir
Commentary
Ottawa’s changes to drug-pricing will deny some Canadians potentially lifesaving drugs
Appeared in the Globe and Mail
| by:
Dr. Nigel Rawson
| by:
Dr. Nigel Rawson
Commentary
Government's pharmacare plan raises more questions than answers
Appeared in the Toronto Sun
| by:
Bacchus Barua,
and Dr. Nigel Rawson
Commentary
Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare
Appeared in the Vancouver Province
| by:
Dr. Nigel Rawson,
and Bacchus Barua
Commentary
Is Ottawa competent enough to design an efficient and effective national pharmacare program?
| by:
Dr. Nigel Rawson,
and Bacchus Barua
| by:
Dr. Nigel Rawson
Commentary
Increasing barriers for drug manufacturers may ultimately hurt patients
Appeared in the Moncton Times & Transcript
| by:
Dr. Nigel Rawson
Commentary
Ottawa’s revisions to drug-pricing review board will delay or prevent access to new drugs
Appeared in the Hamilton Spectator
| by:
Dr. Nigel Rawson